APAC treatment limits collar-induced carotid atherosclerotic plaque development in apoE-/- mice
Bot, I.; Delfos, L.; Hemme, E.; Kovanen, P.T.; Jouppila, A.; Lassila, R.

Citation

Version: Publisher's Version
License: Licensed under Article 25fa Copyright Act/Law (Amendment Taverne)
Downloaded from: https://hdl.handle.net/1887/3494142

Note: To cite this publication please use the final published version (if applicable).
APAC treatment limits collar-induced carotid atherosclerotic plaque development in apoE-/- mice

Doctor Bot I, Miss Delfos L, Miss Hemme E, Professor Kovanen PT, Doctor Jouppila A, Professor Lassila R

Leiden Academic Centre for Drug Research, BioTherapeutics, Leiden, Netherlands (The)
Wihuri Research Institute, Helsinki, Finland
Clinical Research Institute HUCH, Helsinki, Finland
Aplagon Ltd., Helsinki, Finland

Funding Acknowledgements: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Dutch Heart Foundation

Introduction and aim: Mimics of mast cell-derived heparin proteoglycans (HEP-PG) can be tailored to molecules carrying both antiplatelet and anticoagulant properties. These dual antiplatelet and anticoagulant (APAC) constructs can also shield adhesion molecules such as P-selectin and VCAM-1 expressed by endothelial cells upon atherosclerosis development. We hypothesize that via this way, APAC prevents macrophage accumulation and lesion development. In this study, we therefore determined the efficacy of APAC in inhibiting atherosclerosis.

Methods: Male western-type diet fed apoE-/- mice were equipped with perivascular carotid artery collars to induce atherosclerosis. In this collar model, mRNA expression of adhesion molecules such as ICAM-1, VCAM-1, P-Selectin but also of Platelet Factor 4 (PF4) are significantly upregulated upon lesion development (all $P<0.05$ at 2 weeks after collar placement compared with control arteries). From lesion initiation, mice were treated with $0.2 \text{mg/kg}$ APAC or vehicle control (i.v., 3x per week, $n=12-14$ per group) for 2.5 weeks. At 5 weeks after collar placement, mice were sacrificed.

Results: APAC treatment did not affect body weight or plasma total cholesterol levels of the mice during the experiment. Interestingly, carotid artery plaque size was reduced by over 50% upon APAC treatment ($50\pm10\times10^3$ versus controls: $102\pm13\times10^3$ square $\mu$m; $P<0.01$). This observation was aligned with reduced plaque macrophage area (APAC: $20\pm5\times10^3$ versus controls: $33\pm5\times10^3$ square $\mu$m) and collagen content (APAC: $13\pm4\times10^3$ versus controls: $28\pm6\times10^3$ square $\mu$m; $P<0.05$).

Conclusion: We here show that APAC effectively inhibits atherosclerotic lesion development when administered during lesion initiation and may have potential as therapeutic agent to prevent atherosclerosis.